Pharmacophore identification of KSP inhibitors.

A three-dimensional pharmacophore model was developed based on 25 currently available KSP (kinesin spindle protein) inhibitors in Catalyst software package. The best pharmacophore hypothesis (Hypo1), consisting of four chemical features (one hydrogen-bond acceptor, one hydrogen-bond donor, one aromatic ring, and one hydrophobic group), has a correlation coefficient of 0.965. The results of our study provide a valuable tool in designing new leads with desired biological activity by virtual screening.

[1]  Torsten Wittmann,et al.  The spindle: a dynamic assembly of microtubules and motors , 2001, Nature Cell Biology.

[2]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[3]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 1. Validation and Estimation of Coverage , 1995, J. Chem. Inf. Comput. Sci..

[4]  Wayne Vaccaro,et al.  Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tetrahydroisoquinoline lead series. , 2006, Bioorganic & medicinal chemistry letters.

[5]  W. F. Hoffman,et al.  Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. , 2006, Bioorganic & medicinal chemistry letters.

[6]  P. Renhowe,et al.  Inhibitors of kinesin motor proteins--research and clinical progress. , 2005, Current opinion in drug discovery & development.

[7]  G. Gundersen.  Evolutionary conservation of microtubule-capture mechanisms , 2002, Nature Reviews Molecular Cell Biology.

[8]  Paul J Coleman,et al.  Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. , 2005, Bioorganic & medicinal chemistry letters.

[9]  W. F. Hoffman,et al.  Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. , 2006, Bioorganic & medicinal chemistry letters.

[10]  Andrew Smellie,et al.  Analysis of Conformational Coverage, 2. Applications of Conformational Models , 1995, J. Chem. Inf. Comput. Sci..

[11]  L. Mueller,et al.  Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[12]  Gautier Robin,et al.  In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. , 2004, Molecular cancer therapeutics.

[13]  T. Kapoor,et al.  HR22C16: a potent small-molecule probe for the dynamics of cell division. , 2003, Angewandte Chemie.

[14]  T. Mitchison,et al.  Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Russell L. Malmberg,et al.  A standardized kinesin nomenclature , 2004, The Journal of cell biology.

[16]  K. Wood,et al.  Antitumor activity of a kinesin inhibitor. , 2004, Cancer research.

[17]  Youwei Yan,et al.  Kinesin spindle protein (KSP) inhibitors. Part 4: Structure-based design of 5-alkylamino-3,5-diaryl-4,5-dihydropyrazoles as potent, water-soluble inhibitors of the mitotic kinesin KSP. , 2006, Bioorganic & medicinal chemistry letters.

[18]  Y. Toyoshima,et al.  A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5. , 2003, Chemistry & biology.

[19]  K. Wood,et al.  Past and future of the mitotic spindle as an oncology target. , 2001, Current opinion in pharmacology.